Jennifer Petrie, MD
Family Medicine · Emmett, IDNPI 1891879094
Payments from drug & device makers
Across 108 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$360
- AstraZeneca$298
- Astellas Pharma US Inc$252
- Novo Nordisk$194
- Lilly USA, LLC$163
- GSK$129
- plus $701 from 19 others
What the payments were for
- Food & beverage$1,90291%
- Education$1959%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $360 |
| AstraZeneca | 18 | $298 |
| Astellas Pharma US Inc | 5 | $252 |
| Novo Nordisk | 11 | $194 |
| Lilly USA, LLC | 10 | $163 |
| GSK | 7 | $129 |
| Exact Sciences | 4 | $91 |
| Sanofi-aventis U.S. LLC | 5 | $89 |
| Bayer | 3 | $71 |
| Boehringer Ingelheim | 3 | $65 |
| Corcept Therapeutics | 3 | $56 |
| Nestle Healthcare Nutrition Inc. | 3 | $52 |
| Pfizer | 3 | $43 |
| Soleno Therapeutics, Inc. | 1 | $34 |
| Bardy Diagnostics, Inc. | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Neuronetics, Inc. | 1 | $21 |
| Medtronic | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Biodelivery Sciences International, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Novartis | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$2,097 in reported general payments places this provider in the 80th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 127 | $130,064 |
| MounjaroTirzepatide | 91 | $115,994 |
| OzempicSemaglutide | 60 | $69,558 |
| JardianceEmpagliflozin | 73 | $62,397 |
| TrulicityDulaglutide | 33 | $37,404 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $36,644 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 17 | $29,959 |
| EliquisApixaban | 26 | $22,960 |
| KerendiaFinerenone | 21 | $22,064 |
| Liothyronine Sodium | 378 | $16,264 |
| XareltoRivaroxaban | 15 | $16,141 |
| LinzessLinaclotide | 15 | $8,027 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,368 |
| Invokamet XrCanagliflozin/Metformin Hcl | 11 | $5,658 |
| TradjentaLinagliptin | 11 | $5,449 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $163 | $153,398124 claims |
| AstraZenecaFarxiga | $298 | $130,064127 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $65 | $97,805101 claims |
| Novo NordiskOzempic | $194 | $69,55860 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $129 | $43,01242 claims |
| PfizerEliquis | $43 | $22,96026 claims |
| BayerKerendia | $71 | $22,06421 claims |
| Johnson & JohnsonXarelto | $19 | $16,14115 claims |
| AbbVieLinzess | $360 | $8,02715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 803 family medicine providers in Idaho.
Other family medicine in Emmett
- Tina McGuffeyEmmett$8K
- Mark TurnerMeridian$40.5M
- David ButukMeridian$15.2M
- Gary SoucieBlackfoot$5.8M
- Brock McConneheyBoise$4.5M
- William LaitinenMiddleton$1.1M
- Diane McConneheyBoise$681K
- Flint PackerIdaho Falls$587K
- Paul BeckettBlackfoot$344K
- Elaine DavidsonMeridian$303K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.